During Friday’s Current trade, Shares of Unit Corporation (NYSE:UNT), lost -0.21% to $13.93.
Unit Corporation (UNT) stated its financial and operational results for the second quarter of 2015. Highlights for the quarter comprise:
- Total production of 5.1 million barrels of oil equivalent (MMBoe), a 9% enhance over the second quarter of 2014
- Oil and natural gas liquids (NGLs) production raised 8% over the second quarter of 2014
- Placed three BOSS drilling rigs into service during the quarter
- Gas gathered and gas processed volumes per day raised 11% and 15%, respectively, over the second quarter of 2014
SECOND QUARTER AND FIRST SIX MONTHS 2015 RESULTS
Because of significantly lower commodity prices, Unit’s second quarter of 2015 results comprise the following pre-tax non-cash write downs: $410.5 million ceiling test write down in the carrying value of the company’s oil and natural gas properties and an $8.3 million pre-tax write down for the decline in the carrying value of certain drilling rigs and other assets removed from service. As a result, Unit recorded a net loss of $274.4 million, or $5.58 per share, contrast to net income of $54.4 million, or $1.11 per diluted share, for the second quarter of 2014. Adjusted net loss for the quarter (which excludes the effect of non-cash commodity derivatives and the effects of the write-downs) was $5.9 million, or $0.12 per diluted share (see Non-GAAP Financial Measures below). Total revenues for the quarter were $214.4 million (50% oil and natural gas, 26% contract drilling, and 24% mid-stream), contrast to $405.4 million (49% oil and natural gas, 28% contract drilling, and 23% mid-stream) for the second quarter of 2014.
Unit Corporation, together with its auxiliaries, operates as an oil and natural gas contract drilling company primarily in the United States. The company operates through three segments: Oil and Natural Gas, Contract Drilling, and Mid-Stream. The Oil and Natural Gas segment explores, develops, acquires, and produces oil and natural gas properties primarily located in Oklahoma and Texas, in addition to in Arkansas, Colorado, Kansas, Louisiana, Mississippi, Montana, New Mexico, North Dakota, and Wyoming.
Shares of Qlik Technologies Inc (NASDAQ:QLIK), declined -0.59% to $38.41, during its current trading session.
Qlik® (QLIK), a leader in visual analytics, and Supply Chain Digest (SCDigest), the industry’s premier supply chain administration and logistics publication, recently declared the findings of a global study, Leveraging Supply Chain Data for Competitive Advantage. According to the study, the majority of recently’s supply chain analytics are “looking in the rearview mirror” when it comes to evaluating performance, but realize the potential value of adopting advanced analytics.
More than 40 percent of respondents said they are still almost exclusively backward looking when it comes to data analysis. However the vast majority expressed the belief that predictive analytics would bring value to users enabling them to leverage data at the point of decision. Additionally, more than 88 percent of respondents ranked advanced analytic capabilities as an outstanding or good opportunity for their organization. Respondents also noted that making improvements in data and analytic capabilities was either a high precedingity or something they were already focused on doing.
Qlik Technologies Inc. provides user-driven business intelligence solutions that enable customers to make business decisions. The company develops, commercializes, and implements software products and related services. It offers QlikView, which enables business users to explore data; ask and answer their own stream of questions; and follow their own path to insight on their own, or collaborate across teams and organizations.
PG&E Corporation (NYSE:PCG), during its Friday’s current trading session decreased -0.87% to $53.41.
Pacific Gas and Electric Company (PG&E) has named Melissa Lavinson as Chief Sustainability Officer, an expansion of her existing role as vice president of Federal Affairs.
In her expanded role, Lavinson will be focused on continuous improvement of the company’s national leadership on sustainability practices and policies. She will continue to be based in the company’s Washington, D.C., office.
Lavinson has been with PG&E since 1997, a tenure that has comprised of assignments in California and Washington, D.C., with both the utility and the holding company, PG&E Corporation. In Federal Affairs, she is responsible for directing the company’s public policies on all federal issues that impact PG&E and its customers.
Lavinson is on the boards of the Climate Action Reserve, the Women’s Energy Resource Council, the China-U.S. Energy Efficiency Alliance, and She Should Run, which promotes women’s representation in public office.
PG&E Corporation, through its partner, Pacific Gas and Electric Company, transmits, delivers, and sells electricity and natural gas to residential, commercial, industrial, and agricultural customers primarily in northern and central California. The company’s electricity distribution network comprises of 141,700 circuit miles of electric distribution lines, 55 transmission switching substations, and 603 distribution substations; and electricity transmission network comprises 18,100 circuit miles of interconnected transmission lines and 91 electric transmission substations. Its natural gas system comprises of about 42,700 miles of distribution pipelines, about 6,400 miles of backbone and local transmission pipelines, and various storage facilities.
Finally, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), decreased -0.07%, to $1.39.
AVEO Oncology (AVEO) declared an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, counting modified or derivative forms of any such antibody (the “Product”).
Under the terms of the agreement, AVEO will receive an upfront payment of $15 million and will be eligible to receive reimbursement, clinical, sales and regulatory-based milestone payments totaling $311 million assuming successful advancement of the Product. AVEO will also be eligible to receive tiered royalties on product sales ranging from high single digits to a low double-digit. Novartis will be responsible for all clinical development, manufacturing and commercialization activities and costs associated with the Product.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
